Logo Image
|Articles|October 16, 2020

People and Business News

The latest happenings of the industry from the past month.

People

WCG announced that Carsten Henke has joined the company as Senior Vice President, Europe and Managing Director, Germany.

Former Chief Commercial Officer, Jeremy Edwards, has been appointed CEO of Raremark and former Head of Product, Alex Garner, has become COO.

ActiGraph announced the hiring of Kuno van der Post as Chief Commercial Officer, Lynda Barr as Chief Financial Officer, and Scott Ginnetti as Vice President of Human Resources and Culture.

Medable Inc announced several new hires including Mary Costello as Head of Site and Investigator Network, Rasmus Hogreffe as VP of Decentralized Trial Innovation, Steve Lesser as VP of Partner Strategy, Heidi Pfefferkorn as Decentralized Solutions Leader, Eric Peper as Executive VP of Sales, David Swanger as Senior VP of Marketing, and Ching Tian as Senior VP of Strategy & Solutions.

Recognition

Veeva Systems announced that more than 500 in over 30 countries are using Veeva SiteVault Free.

Oracle Health Sciences, for the 4th year in a row, has been named a “Leader” in the Everest Group Clinical Development Platforms Products PEAK Matrix Assessment 2020. Oracle also maintained its position as the highest positioned vendor in “Vision and Capability” and took the highest position for “Market Impact.”

Syneos Health announced that it was awarded the Society for Clinical Research Sites (SCRS) Eagle Award, for the fourth consecutive year.

Related to this article

View more
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
Read more
What the Epilepsy Community Has Taught Us About Trial Feasibility
What the Epilepsy Community Has Taught Us About Trial Feasibility
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has learned firsthand from families living with Dravet syndrome and CDKL5 deficiency disorder about what makes trial participation possible—and what makes it not.
Read more